Millions of people are now using weight-loss drugs, but it seems there are side-effects that come with the slimmer waistlines ...

Glucagon-like peptide-1 receptor agonist drugs (commonly referred to as GLP-1 agonists) have become widely prescribed for ...

The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple sclerosis.

Oculis, Legacy Healthcare and Neurosterix are advancing their drug pipelines with major clinical milestones. Oculis’ Privosegtor received breakthrough therapy designation from the U.S. Food and Drug ...

Oculis’ neuroprotective candidate privosegtor receives US FDA breakthrough therapy designation to treat optic neuritis: Zug, Switzerland Thursday, January 8, 2026, 17:00 Hrs [IS ...

Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...

“Proper foot massage can significantly improve neuropathy symptoms when used correctly,” stated Dr. Alan Rabinowitz, OSHF’s chief medical advisor. “However, patients must avoid excessive pressure or ...

Please provide your email address to receive an email when new articles are posted on . If approved, privosegtor would become the first neuroprotective therapy for optic neuropathies. The PIONEER 1 ...

When a person suffers a stroke, physicians must restore blood flow to the brain as quickly as possible to save their life. But, ironically, that life-saving rush of blood can also trigger a second ...

The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...

Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...